论文部分内容阅读
许多癌症都依赖于EGFR(表皮生长因子受体)来维持旺盛生长。一些被期望通过关闭这一细胞信号接收位点来起作用的药物,却在大多数患者中没有能够阻止住癌症。在正常细胞中,EGFR发挥功能可使细胞受益。然而在大量的癌症中--从较常见的卵巢癌和皮肤癌到较少见的侵袭性癌症如大脑胶质母细胞瘤--控制EGFR的基因往往被重编程,并生成了太多的EGFR,由此导致了失控性的生长以及癌细胞扩散。威斯康星大学麦迪逊分校Richard A.Anderson实验室的发布
Many cancers rely on EGFR (epidermal growth factor receptor) to maintain vigorous growth. Some drugs that are expected to work by turning off this cellular signal-receiving site are not able to stop cancers in most patients. In normal cells, EGFR functions to benefit cells. However, in a large number of cancers - from the more common ovarian and skin cancers to less common invasive cancers such as glioblastoma - genes that control EGFR are often reprogrammed and generate too much EGFR , Resulting in uncontrolled growth and cancer cell proliferation. University of Wisconsin-Madison, Richard A. Anderson Laboratory